Source comparison
PT-141 Protocol Comparison
On-Demand Only (1 dose/week) 12–18% 25–35% Low (nausea in 25%) Minimal commitment, slower onset Scheduled 2×/Week 20–30% 45–55% Moderate (nausea in 40%) Standard research protocol Front-Loaded (3 doses week 1, 2/week after) 30–40% 55–65% Higher early (nausea i
This comparison does not assign a generated winner or score.
- On-Demand Only (1 dose/week)
- 12–18%
- 25–35%
- Low (nausea in 25%)
- Minimal commitment, slower onset
- Scheduled 2×/Week
- 20–30%
- 45–55%
- Moderate (nausea in 40%)
- Standard research protocol
- Front-Loaded (3 doses week 1, 2/week after)
- 30–40%
- 55–65%
- Higher early (nausea in 50%), decreases by week 3
- Faster receptor saturation
- Daily Dosing (not FDA-approved)
- Unknown
- Very high (nausea >60%)
- Exceeds approved safety limits
- The comparison makes clear that PT-141 results after 1 month improve with consistent twice-weekly dosing, but daily administration is not supported by safety data and significantly increases adverse event risk.